On #RareDiseaseDay, AdBio Partners stands with the rare disease community, committed to transforming bold scientific discoveries into life-changing therapies. Our portfolio—ARTHEx Biotech, SparingVision, Tenpoint Therapeutics, Ltd. , Agomab , Augustine Therapeutics, Calida Therapeutics, Integra Therapeutics, Tridek-One, and more—develops cutting-edge solutions for patients suffering from rare diseases. At AdBio partners, our approach goes beyond funding. We create and support biotech companies from inception, working closely with scientists and entrepreneurs to accelerate innovation. With a deep track record in rare disease investment, we bridge the gap between breakthrough research and real patient impact. Rare diseases may be individually uncommon, but together they affect millions. Today, we reaffirm our mission: bringing hope where there are no options, and pioneering therapies where there are none. #AdBioPartners #RareDiseaseDay #Innovation #Biotech #PatientsFirst
AdBio partners
Directeurs du capital-risque et du capital-investissement
Paris, IDF 3 888 abonnés
AdBio is a VC firm with an entrepreneurial spirit, dedicated to life sciences & focusing on early-stage investments
À propos
AdBio partners focuses on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies. Keeping in mind patients’ well-being, we believe in improving medical care and taking medical innovations further ahead. We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. We embrace French Life Sciences’ dynamic of innovation. France harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. Adbio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring France’s biotechnology ecosystem. Adbio partners was founded in 2015 and is AMF regulated since 2016.
- Site web
-
http://www.adbio.partners
Lien externe pour AdBio partners
- Secteur
- Directeurs du capital-risque et du capital-investissement
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Paris, IDF
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2016
Lieux
-
Principal
Obtenir l’itinéraire
4 rue Thénard
75005 Paris, IDF, FR
Employés chez AdBio partners
Nouvelles
-
[Event] Exciting news ahead! Our Operating Partner Alejo Chorny, co-founder and CSO of Orikine Bio is set to take the stage at the upcoming Cytokine Based Drug Development Summit on May 15-16 in Boston. Alejo will discuss breakthrough approaches in cytokine engineering for hard-to-treat autoimmune and inflammatory diseases. At Adbio Partners, we invest in innovative science that drives real progress in patient care. Orikine Bio focuses on developing next-generation assets that address unmet needs in autoimmune and inflammatory diseases https://www.orikine.bio/ Learn more about the summit here: https://lnkd.in/e635MQXk #AdbioPartners #CytokineBasedDrugDevelopment #InnovativeScience #PatientFirst #PharmaInnovation
-
-
[Porfolio] Great news from our portfolio company SparingVision! Their lead investigational gene therapy, SPVN06, continues to show a favorable safety profile in clinical development. The data were presented at the Macula Society 48th Annual Meeting last week. At AdBio partners, we are proud to support SparingVision in its mission to bring transformative treatments to patients with retinal diseases. #GeneTherapy #Ophthalmology #RetinitisPigmentosa #Biotech #AdBioPartners Stephane Boissel
📢 SparingVision announces presentation of SPVN06 safety data at the Macula Society 48th Annual Meeting Professor Isabelle audo presented the latest safety data on SPVN06, our lead investigational gene therapy for retinitis pigmentosa. ✅ Key Findings: ✔️ Favorable safety profile maintained across all patient cohorts ✔️ Up to 12-month follow-up data for low dose and 6-month data for medium dose cohorts (n=6) ✔️ 3-9 month data for high-dose cohort (n=3) ✔️ No significant intraocular inflammation, serious adverse events, or study discontinuations 👉 Read more about this breakthrough: https://lnkd.in/efvDSbvJ #GeneTherapy #RetinalDisease #RetinitisPigmentosa #Ophthalmology #ClinicalTrials
-
[Portfolio news] Exciting news from Augustine Therapeutics ! We’re very happy to welcome Gerhard Koenig as CEO at a pivotal time for the company as it advances its best-in-class HDAC6 inhibitors toward the clinic. At AdBio partners, we take pride in backing breakthrough science from the very start—helping European innovation grow and attract top-tier talents. Augustine’s journey is yet another example of how our portfolio companies scale to global leadership in biotech. We look forward to seeing what’s next! 🌍💡 #VentureCapital #Biotech #AdBioPartners #EarlyStageInnovation #ScalingBiotech Alain Huriez Adrien C. Sylvain Celanire VIB KU Leuven
Today we announced that industry veteran and our current Executive Chairman Gerhard Koenig has become our CEO. This #appointment comes at exciting time for #AugustineTherapeutics as we look to progress our potentially best-in-class highly selective HDAC6 inhibitor disease-modifying treatments for neuromuscular, neurodegenerative and cardiometabolic diseases into the clinic. Gerhard has more than 30 years of drug development experience and was previously CEO and Co-founder of Arkuda Therapeutics which was focused on the development of lysosomal function enhancers for the treatment of neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease. Arkuda’s portfolio of lysosomal function enhancers was acquired by Johnson & Johnson and announced last month. More information: https://lnkd.in/e32Tx6B3 #HDACs #AugustineTx #neuromusculardiseases #neurodegenerativediseases #cardiometabolicdiseases #CMT #CMTA #CharcotMarieTooth
-
-
[Event] What does it take to catch an investor’s eye in RNA? Join Adrien C., Principal at AdBio Partners, at RNA Leaders in Basel next month. As an experienced investor in early-stage biotech, Adrien will join a stellar panel of experts to discuss: 🔹 Key innovation areas in RNA that investors are watching 🔹 How startups can stand out in a competitive funding landscape 🔹 Insider tips on pitching and strategic partnerships Check ou the full agenda and speakers below 👇
𝐏𝐀𝐍𝐄𝐋 𝐀𝐍𝐍𝐎𝐔𝐍𝐂𝐄𝐌𝐄𝐍𝐓 – 𝐑𝐍𝐀 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 𝐄𝐮𝐫𝐨𝐩𝐞! What are investors looking out for in RNA? Hear directly from leading investors on what they prioritise and how you can stand out at RNA Leaders Basel in just one month including: 🔹 Get insider tips on pitching to maximise your strategic partnership opportunities 🔹 Explore the key areas where investors see the most innovation in RNA 🔹 Gain insights into the current investment landscape for RNA modalities and enabling platforms Download the agenda to see the full lineup of sessions and speakers -https://lnkd.in/e6-EqS5N &utm_campaign=rnaeu25 Find out more about RNA Leaders Europe Congress - https://lnkd.in/e_ifRSDV &utm_campaign=rnaeu25 Panel features: Paola Pozzi, Partner, Sofinnova Telethon Fund at Sofinnova Partners Michael Kyriakides, Partner at Syncona Limited Marianne Mertens, Partner at Apollo Health Ventures Adrien C., Principal at AdBio partners Kristin Thompson, Investment Director at Merieux Equity Partners
-
-
[Event] Join us at Apéro Innovation on Feb 13th @Hôtel-Dieu in Paris ! At AdBio partners, we are dedicated to backing breakthrough science that transforms patient care. That’s why we’re thrilled to take part in this special session on #migraine treatment innovation. Our Managing Partner Clément Bertholet will present how emerging biotech startups are bringing new hope to patients suffering from migraines alongside Jes Olesen, Palle Christophersen key innovators in the field & Donmienne Leung from AbbVie Ventures. Thank you BioLabs France ! Register below 👇 #AdBioPartners #Biotech #Innovation #PatientsFirst BioLabs Université Paris Cité AP-HP, Assistance Publique - Hôpitaux de Paris
Join us for the next Apéro Innovation @Hôtel-Dieu! Get ready for an inspiring session as we dive into the latest advancements in migraine treatment. This edition of Apéro Innovation @Hôtel-Dieu will bring together key voices from the healthcare, startup, and investment ecosystems to explore how innovation is reshaping migraine care. 🧠 🔹 Speakers: ✅ Jes Olesen (#Cephagenix) – sharing industry insights on migraine research ✅ Palle Christophersen & Clément Bertholet (AdBio partners) – presenting innovative startup solutions ✅ Donmienne Leung (AbbVie Ventures) – offering an investor’s perspective on healthtech innovation Don’t miss the chance to engage in thought-provoking discussions and connect with the community over drinks. 🍷 📅 February 13, 2025 ⏰ 6:00 PM – 7:30 PM 📍 Hôtel-Dieu, Amphithéâtre Dupuytren 🔗 Register now: https://lnkd.in/dffXNG_D We look forward to seeing you there! 🚀
-
-
[Portfolio news] Very proud to share that SparingVision's lead product SPVN06 will enter Phase II studies to evaluate the efficacy of this new gene-agnostic approach for patients suffering from rod-cone dystrophy, a debilitating ophthalmology disease. Following positive safety results, the independent Data Safety Monitoring Board (DSMB) has recommended continuation to the extension phase (Step 2) of the Phase I/II PRODYGY trial. Congratulations to the team ! #rarediseases #biotech #genetherapy Stephane Boissel
📢 Breaking News: SPVN06 Advances to Phase II! We are delighted to announce that following review of safety data, the independent Data Safety Monitoring Board (DSMB) has recommended continuation of the PRODYGY trial into phase II.✨ 🚀 The Phase II extension phase will evaluate medium and high doses of our lead gene-agnostic investigational gene therapy product, SPVN06, in 24 patients with advanced intermediate rod-cone dystrophy (RCD). 👁️🧬This milestone underscores our commitment to advancing innovative treatments for prevalent blinding retinal diseases. We are incredibly grateful to our PIs, partners and our fantastic team for their work and unwavering support as we continue on our journey to make a difference in the lives of those affected by Inherited Retinal Diseases (IRDs). 📰Stay tuned for updates as we progress through this exciting phase of the PRODYGY trial! more info: https://lnkd.in/e9SbcDbd #SPVN06 #PRODYGYTrial #GenomicMedicines #GeneTherapy #RetinalDisease
-
[News] Congratulations to Clément Bertholet, Adrien C. and Geoffroy De Ribains for their promotions and new responsibilities 👏
Très heureux d'annoncer les promotions de Clément Bertholet comme Managing Partner et d'Adrien Clavairoly comme Principal et de féliciter Geoffroy de Ribains pour ses nouvelles responsabilités opérationnelles comme Venture Partner. Very happy to announce the promotions of Clement Bertholet as Managing Partner and Adrien Clavairoly as Principal, and to congratulate Geoffroy de Ribains for his new operational responsibilities as Venture Partner. Clément Bertholet Adrien C. Geoffroy De Ribains
-
AdBio partners a republié ceci
AdBio partners renforce son département financier et middle office et recrute notamment un(e ) directeur (trice) finances et reporting. Dans le cadre de son développement, la société de gestion AdBio partners, www.adbio.partners, leader français et européen de l’investissement early stage en sciences de la vie, renforce son département financier et middle office et recrute notamment un(e ) directeur (trice) finances et reporting. Les responsabilités principales couvriront : 1/ FPCI · Supervision du lancement de nouveaux fonds · Validation des projets d’investissement et de désinvestissement dans leurs aspects réglementaires · Gestion des appels de fonds · Participation aux comités de valorisation trimestriels · Production des comptes annuels, rapports annuels et trimestriels à destination des souscripteurs · Relations investisseurs (LPs) 2/ Société de gestion et FPCI · Suivi des aspects RCCI · Reporting destinés à l’écosystème (AMF, France Invest etc.) au titre des fonds et de la société de gestion · Gestion des interactions avec les prestataires (RCCI délégué, comptable, dépositaire, CAC) · Supervision des aspects ESG des fonds et de la société de gestion Le/ la candidat(e ) devra pouvoir justifier d’une expérience d’au moins 10 ans dans une société de gestion ou un environnement bancaire ou assuranciel, d’une expérience des outils automatisés de reporting. Autonomie et rigueur, capacité à évoluer dans un environnement dynamique et réactif, maitrise de l’anglais sont des éléments importants pour ce poste, qui pourra être rapidement évolutif en fonction des capacités individuelles. CV et lettre de motivation à adresser à contact@adbio.partners
-
[Portfolio news] We are thrilled to announce that our portfolio company, Tenpoint Therapeutics, Ltd., has reported positive topline results from their Phase 3 pivotal trial, BRIO-II, evaluating BRIMOCHOL™ PF for the treatment of presbyopia. BRIMOCHOL™ PF is a combination of carbachol and brimonidine tartrate designed to improve near vision by inducing a "pinhole effect" through pupil modulation. In the BRIO-II study, it demonstrated statistically significant improvements in near vision at all time points over 8 hours and the treatment was well-tolerated over 12 months of continuous dosing. The study enrolled 629 subjects across 47 sites in the United States. These promising results bring Tenpoint Therapeutics closer to providing an innovative, non-invasive solution for the millions affected by presbyopia. Big congrats to the team ! Ben Bergo Henric Bjarke Tim Grinstead #Biotechnology #Presbyopia #ClinicalTrials #Innovation #EyeCare #AdBioPartners
📣 Breaking News 📣 Tenpoint Therapeutics, Ltd. and Visus Therapeutics, Inc. today announce the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. “We are excited to lead with a robust ophthalmology pipeline, starting with BRIMOCHOL™ PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat cataract and geographic atrophy,” said CEO Henric Bjarke. “The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL™ PF and advance innovative products into clinical development to meet unmet needs in ocular diseases,” said David Guyer, MD. Read the press release to learn more about the merger and the breakthrough therapies in the pipeline: https://bwnews.pr/3ZOhNiJ #Presbyopia #Ophthalmology #EyeCare #Pharmaceutical #Biotechnology #Retina